Antibodies specific to CD47 and PD-L1
AssigneeJoint Stock Company “Biocad”
InventorsKirill Vladimirovich SOLOVYEV, Andrei Borisovich ULITIN, Timofey Aleksandrovich NEMANKIN, Valery Vladimirovich SOLOVYEV, Dmitry Valentinovich MOROZOV
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of bioengineering, specifically to antibodies or their antigen-binding fragments, and to the use thereof. More particularly, the present invention relates to antibodies that bind specifically to CD47 and PD-L1. The invention also relates to a nucleic acid that codes for the given antibody or for the antigen-binding fragment thereof, to an expression vector, to a method of producing the antibody, and to a use of the aforementioned antibodies and compositions in cancer treatment.
Claims30
A monoclonal antibody, which specifically binds to CD47 and PD-L1, comprising one binding site to CD47, and at least one binding site to PD-L1.
6 The antibody according to claim 1, characterized in that the binding site to CD47 includes the heavy chain variable domain that containes CDR1, CDR2, CDR3 sequences, wherein CDR1 is a sequence selected from the following group of SEQ ID NOs:
- 1-4, wherein CDR2 is a sequence selected from the following group of SEQ NOs:
- 6-15, wherein CDR3 is a sequence selected from the following group of SEQ ID NOs:
- 17-20.
Dependencies are inferred from the claim text.